Pasithea Therapeutics Corp. (KTTA) on Monday said the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to PAS-004 for the treatment of Neurofibromatosis Type 1 (NF1), a rare genetic disorder.
The designation makes the program eligible for a Priority Review Voucher if the drug is approved, which can be used for faster regulatory review of another product or sold to another company. Pasithea said recent voucher sales have ranged between $150 million and $205 million.
The company noted that a Phase 1/1b study of PAS-004 is currently underway in adult patients with symptomatic, inoperable or recurrent NF1-related plexiform neurofibromas.
Pasithea stock had closed at $0.7424 on Friday, up 0.87%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.